Gerald Commissiong, CEO of Amarantus to Participate in Twitter Chat, "The Human Brain"
SAN FRANCISCO, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that the Company's President and CEO, Gerald E. Commissiong will participate in a Twitter chat tonight at 9:00 PM ET on the topic, "The Human Brain."
The purpose of these ongoing chats is to connect students with scientists in discussions on various scientific subjects. To follow the chat use #scistuchat.
"My goal in participating in these types of events is to spark scientific interest in the minds of young people," said Gerald Commissiong.
Mr. Commissiong will be joining through his personal twitter account @g_commish.
#Scistuchat (cy-stew-chat) is a monthly Twitter Chat with scientists and high school students. Students and Scientists discuss general science topics once a month. Topics might include: genetically modified food, cloning, stem cell research and others, space exploration funding, evolution, etc. The discussion takes place on the 2nd Thursday of the month September through May.
For more information please visit https://sites.google.com/site/scistuchat/
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolind-related apoptosis. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com , or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
CONTACT: Investor/Media Contacts Aimee Boutcher, Director of Investor Relations Amarantus Bioscience Holdings, Inc. 973 332-0121 firstname.lastname@example.org
Source: Amarantus BioScience Holdings, Inc. 2014 GlobeNewswire, Inc.